Casting light into the complex landscape of protein engineering and empowering human health. From diabetes, to cancer, to genetic and chronic diseases, there's a commonality within each that has impacted patients' wellness: their treatments utilize protein therapeutics. BioHybrid Solutions' world renowned scientists are spearheading innovations in protein therapeutics by solving a problem facing the pharmaceutical industry: How can we create longer-lived, more effective medicine?
While getting to an answer wasn't simple, it has arrived. Our proprietary technology Nanoarmors the surface of proteins, enabling them to work better in the human body. Developed at Carnegie Mellon University, our next-generation NanoArmored protein-polymer conjugates with scalable capabilities perfectly suited for advanced therapeutics. We partner with organizations like the NSF, DEP, DoD and DTRA.
A NanoArmored stomach-acid resistant oral enzyme replacement therapy (lipase, amylase, protease) with increased stability, lifetime and activity in the stomach and intestine.
While getting to an answer wasn't simple, it has arrived. Our proprietary technology Nanoarmors the surface of proteins, enabling them to work better in the human body. Developed at Carnegie Mellon University, our next-generation NanoArmored protein-polymer conjugates with scalable capabilities perfectly suited for advanced therapeutics. We partner with organizations like the NSF, DEP, DoD and DTRA.
A NanoArmored stomach-acid resistant oral enzyme replacement therapy (lipase, amylase, protease) with increased stability, lifetime and activity in the stomach and intestine.
Services
BioHybrid Solutions (BHS), is a transformational platform company that develops next-generation NanoArmored protein-polymer conjugates.
Using proprietary technology originally developed at Carnegie Mellon University, proteins are rationally and precisely modified with polymers to dramatically improve their stability and performance.
The BHS platform can be applied across the $150 billion biocatalysis and therapeutics marketplace to dramatically improve protein performance.
In addition, we also open the door to new routes of administration (such as injectable to oral), improved pharmacodynamics/pharmacokinetics, and reduced immunogenicity.
Using proprietary technology originally developed at Carnegie Mellon University, proteins are rationally and precisely modified with polymers to dramatically improve their stability and performance.
The BHS platform can be applied across the $150 billion biocatalysis and therapeutics marketplace to dramatically improve protein performance.
In addition, we also open the door to new routes of administration (such as injectable to oral), improved pharmacodynamics/pharmacokinetics, and reduced immunogenicity.
Unlike traditional PEGylation techniques in which polymer chains are grafted to proteins with little control, the BHS technology utilizes atom transfer radical polymerization (ATRP), a chemistry invented by co-founder Dr. Matyjaszewski, which grows polymers with precision from the surface of proteins.
This new approach results in higher density coverage of the protein with application-specific polymers, improving stability and bioavailability.
Billions of years of molecular evolution have directed nature to synthesize polymers with controlled sequences and configurations.
This new approach results in higher density coverage of the protein with application-specific polymers, improving stability and bioavailability.
Billions of years of molecular evolution have directed nature to synthesize polymers with controlled sequences and configurations.
Enabling more patient friendly routes of administration, reduced immunogenicity and improved pharmacodynamics and pharmacokinetics.
Combining the power of computational science, synthetic chemistry and biology, BHS introduces a new era of therapeutic tools that overcome the limitations of PEGylation technology.
Biohybrid Solutions' innovators have developed a proprietary understanding of structure-function interactions between polymers and biological molecules, resulting in new synthetic processes, materials, applications, and therapies.
Combining the power of computational science, synthetic chemistry and biology, BHS introduces a new era of therapeutic tools that overcome the limitations of PEGylation technology.
Biohybrid Solutions' innovators have developed a proprietary understanding of structure-function interactions between polymers and biological molecules, resulting in new synthetic processes, materials, applications, and therapies.
Reviews
Be the first to review Biohybrid Solutions.
Write a Review
